Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer a prospective randomized controlled trial

Annals of Surgery

Volumn 248, Issue 6, 2008, Pages 1031-1040

  Morak, Marjolein J M ^a   Van Der Gaast, Ate ^a   Incrocci, Luca ^a   Ven Dekken, Herman ^a   Hermans, John J ^a   Jeekel, Johannes ^a   Hop, Wim C J ^a   Kazemier, Geert ^a   Van Eijck, Casper H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; HEPARIN; MITOXANTRONE; 2 AMINOCYCLOPENTANECARBOXYLIC ACID; ANTINEOPLASTIC AGENT; CYCLOLEUCINE; DRUG DERIVATIVE; LEAD; LEAD SULFIDE; SULFIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CELIAC ARTERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; THROMBOSIS; VATER PAPILLA CARCINOMA; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BILE DUCT TUMOR; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME; VATER PAPILLA;

ADENOCARCINOMA; ADULT; AGED; AMPULLA OF VATER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMMON BILE DUCT NEOPLASMS; CYCLOLEUCINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEAD; MALE; MIDDLE AGED; MITOXANTRONE; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; SULFIDES; TREATMENT OUTCOME;

EID: 58149393693     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318190c53e     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradio- therapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585.
3. Willett CG, Czito BG, Bendell JC. Adjuvant therapy of pancreatic cancer. Cancer J. 2007;13:185-191.
4. Bassi C, Stocken DD, Olah A, et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg. 2005;22:353-363.
5. Kennedy EP, Yeo CJ. The case for routine use of adjuvant therapy in pancreatic cancer. J Surg Oncol. 2007;95:597-603.
6. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
7. Baumel H, Huguier M, Manderscheid JC, et al. Results of resection for cancer of the exocrine pancreas: a study from the French association of surgery. Br J Surg. 1994;81:102-107.
8. Klinkenbijl JH, Jeekel J, Schmitz PI, et al. Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg. 1993;80: 1575-1578.
9. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg. 1995;221:133-148.
10. Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221:59-66.
11. Trede M. The surgical treatment of pancreatic carcinoma. Surgery. 1985;97:28-35.
12. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447-458.
13. Wade TP, Coplin MA, Virgo KS, et al. Periampullary cancer treatment in US Department of Veterans affairs hospitals: 1987-1991. Surgery. 1994;116:819-825; discussion 825-826.
14. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221: 721-731; discussion 731-733.
15. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006 -2010.
16. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120:899-903.
17. The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorou- racil for locally unresectable pancreatic carcinoma. Ann Surg. 1979;189: 205-208.
18. Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 1985;56:2563-2568.
19. Neoptolemos JP, Cunningham D, Friess H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol. 2003; 14:675-692.
20. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782; discussion 782-784.
21. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246:734-740.
22. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758-768.
23. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl JMed. 2004;350:1200-1210.
24. Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs. 2007;67:2293-2310.
25. Picozzi VJ, Pisters PW, Vickers SM, et al. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008;12:657-661.
26. Hayashibe A, Kameyama M, Shinbo M, et al. Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer. Ann Surg Oncol. 2007;14:190-194.
27. Beger HG, Gansauge F, Buchler MW, et al. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg. 1999;23:946-949.
28. Ishikawa O, Ohhigashi H, Sasaki Y, et al. Extended pancreatectomy and liver perfusion chemotherapy for resectable adenocarcinoma of the pancreas. Digestion. 1999;60(suppl 1):135-138.
29. Blackstock AW, Mornex F, Partensky C, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br JCancer. 2006;95:260-265.
30. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. Hoboken, New Jersey: John Wiley; 2002.
31. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10-15.
32. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pan- creaticobiliary carcinoma. Cancer. 2002;95:1685-1695.
33. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476-480.
34. Knaebel HP, Marten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma-CapRI: study protocol [ISRCTN62866759]. BMC Cancer. 2005;5:37.
35. Vitale G, van Eijck CH, van Koetsveld Ing PM, et al. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg. 2007;246:259 -268.
36. Link KH, Kornmann M, Leder G, et al. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU+ folinic acid and mitomycin C. Gan To Kagaku Ryoho 1999;26: 269-281.